Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.69 |
| ▸ | CMKLR1 | Q99788 | 3/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13140179 | 0.89 | FFAR1 (0.56) | FFAR1CMKLR1PSMB5 | |
| SCHEMBL13140176 | 0.89 | FFAR1 (0.71) | FFAR1CMKLR1 | |
| SCHEMBL13140189 | 0.88 | FFAR1 (0.79) | FFAR1CMKLR1 | |
| SCHEMBL13118244 | 0.85 | FFAR1 (0.80) | FFAR1 | |
| SCHEMBL14495981 | 0.84 | FFAR1 (0.72) | FFAR1CMKLR1 | |
| SCHEMBL13139960 | 0.83 | FFAR1 (0.69) | FFAR1CMKLR1 | |
| SCHEMBL13139958 | 0.81 | FFAR1 (0.69) | FFAR1CMKLR1 | |
| SCHEMBL13140560 | 0.81 | FFAR1 (0.69) | FFAR1CMKLR1 | |
| SCHEMBL13140168 | 0.80 | FFAR1 (0.79) | FFAR1 | |
| SCHEMBL8162876 | 0.79 | FFAR1 (0.67) | FFAR1CMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | FFAR1 1245/4885CMKLR1 1202/4885PSMB5 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.